Halo develops disease-modifying therapies by selectively editing components of the extracellular matrix (ECM). Their approach aims to restore homeostasis in diseases characterized by inflammation and fibrosis, with a lead program targeting pulmonary hypertension.
Funding
Funding not disclosed
Founders
Product
Problem
Pulmonary hypertension and interstitial lung disease are characterized by inflammation and fibrosis, leading to significant morbidity and mortality. Current treatments often fail to address the underlying disease mechanisms, resulting in limited efficacy and disease progression. Dysregulation of the extracellular matrix (ECM), particularly hyaluronan (HA), contributes to these pathological processes.
Solution
Halo Biosciences is developing disease-modifying therapies that target the ECM to restore homeostasis in inflammatory and fibrotic diseases, with an initial focus on pulmonary hypertension and interstitial lung disease. Their lead candidate, H1614, is a proprietary reformulation of 4-methylumbelliferone (4-MU), a small molecule inhibitor of hyaluronan synthesis. By inhibiting HA synthesis, H1614 aims to down-regulate inflammatory and fibrotic cell-signaling pathways, addressing the underlying mechanisms of disease progression. Clinical data from Phase 1 and Phase 2a studies suggest that targeting the HA pathway can lead to functional improvements in patients with pulmonary hypertension. H1614 is positioned as a potential first-in-class hyaluronan remodeling agent ready for clinical study in 2026.
Target Audience
The primary target audience includes patients suffering from pulmonary hypertension and interstitial lung disease, as well as physicians specializing in pulmonary medicine.
Features
- H1614: A proprietary reformulation of 4-methylumbelliferone (4-MU) designed for improved bioavailability and efficacy.
- Inhibition of hyaluronan (HA) synthesis: Reduces inflammation and fibrosis by targeting a key component of the ECM.
- Disease-modifying potential: Aims to address the underlying mechanisms of pulmonary hypertension and interstitial lung disease, rather than just managing symptoms.
- Clinical validation: Positive Phase 1 data demonstrating reduction in hyaluronan levels in the lungs of study participants.
- FDA Orphan Drug Designation: Secured for 4-MU in the indication of primary sclerosing cholangitis.